AHK-Cu Copper Peptide (Alanine-Histidine-Lysine Copper, AHK-Cu Tripeptide)

AHK-Cu is a copper-binding tripeptide that's gained attention in the hair restoration space as a complement or alternative to the better-known GHK-Cu. While GHK-Cu has a broad evidence base covering wound healing, skin rejuvenation, and general tissue repair, AHK-Cu has been specifically investigated for its effects on hair follicle dermal papilla cells, the specialized fibroblasts that regulate hair growth. The key study is from Pyo et al. (PMID: 17918218), who tested multiple copper-binding peptides on cultured human dermal papilla cells. AHK-Cu stimulated VEGF (vascular endothelial growth factor) production and cell proliferation more effectively than several other copper peptide variants tested. VEGF is important for hair growth because it promotes blood vessel formation around hair follicles, and impaired follicular vasculature is one factor in progressive miniaturization seen in androgenetic alopecia. The distinction between AHK-Cu and GHK-Cu is worth understanding. GHK-Cu (glycyl-L-histidyl-L-lysine copper) has hundreds of published studies and a well-documented role in tissue remodeling through multiple pathways: collagen synthesis, glycosaminoglycan production, anti-inflammatory effects, and gene expression modulation (it upregulates hundreds of genes involved in tissue repair). AHK-Cu (alanyl-L-histidyl-L-lysine copper) shares the histidine-lysine copper-binding motif but has a different N-terminal amino acid, which alters its receptor interactions and potentially its tissue specificity. In practice, AHK-Cu is used primarily in two ways: topical scalp serums at 50-200 ppm concentration, and mesotherapy (direct scalp injection) at 1-5 mg per session. The topical route requires consistent daily application for 3-6 months to see results, which aligns with the hair growth cycle timeline (telogen-to-anagen transition takes months). Mesotherapy delivers the peptide directly to the dermal papilla layer, bypassing the skin penetration barrier, and is typically performed monthly. The evidence gap is honest: AHK-Cu has promising in vitro data but lacks published controlled clinical trials for hair growth in humans. This puts it in a similar position to many cosmeceutical peptides: the mechanism makes biological sense, the in vitro results are positive, but we don't have the randomized controlled trial data to quantify efficacy or optimal dosing in humans. For anyone considering AHK-Cu, combining it with established hair loss treatments (minoxidil, finasteride for men, low-level laser therapy) is a practical approach. The mechanisms are complementary: AHK-Cu provides growth factor stimulation and follicular vascularity support, while minoxidil is a direct vasodilator and finasteride addresses the hormonal component. Cost is modest at $40-120/month, making it an accessible add-on to a hair restoration protocol.